Skip to main content

Plasma Cell Dyscrasia clinical trials at UCSF

1 in progress, 0 open to eligible people

Showing trials for
  • Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy

    Sorry, not yet accepting patients

    The complex logistics and unique toxicities of chimeric antigen receptor T-cell (CAR-T) therapy require intensive patient education and careful monitoring. The Companion for CAR-T (CC) web app may be able to assist with patient education and preparation, communication between patients and their multidisciplinary teams, and home-based toxicity monitoring.

    San Francisco, California

Our lead scientists for Plasma Cell Dyscrasia research studies include .

Last updated: